Drugs / TAK-226
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07319845 | Apr 2026 → Jun 2028 expected | myelodysplastic syndrome | Takeda | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07319845 ↗ |
| Route | Subcutaneous | “TAK-226 subcutaneous injection” NCT07319845 ↗ |